2026Year01Month20Day,Bayer AGDeveloped by1Radiation-like therapeutic drugsBAY 3547926The clinical trial application for the "Injection" has received the tacit approval from the Center for Drug Evaluation of the National Medical Products Administration, allowing it to proceed.“Hepatocellular Carcinoma (HCC）”Clinical research.

BAY 3547926Injection solution adopts monoclonal antibody conjugationAc-225Technical route, the drug isBayerThe Third in Clinical DevelopmentTATProject, alsoBayerFirst TreatmentHCCTargetedGPC3Radiopharmaceuticals. This approval marksBAY 3547926Officially entering the Chinese R&D pipeline, also becoming the fifth company in China to receive approval to conductAc-225Radionuclide registration clinical research companies. ButBayerIt is completely different from the other four, Novartis, Lanacheng,Full-Life(Fluorine Link) and Tongrui Biotech are still focused on prostate cancer.PSMATarget. As a multinational pharmaceutical company that entered the radiopharmaceuticals track earlier than Novartis, Bayer's launch of its first targeted radioactive drug for liver cancer in China is not only an important implementation of its radiopharmaceutical strategy, but also highlights the century-old company’s deep cultivation and foresight in the field of precision medicine.

The clinical approval of "BAY 3547926"Injection" as1A new class of drugs (innovative drugs not yet marketed in China or abroad), targeting hepatocellular carcinoma (HCC) is the sixth most common cancer globally and the third leading cause of cancer-related deaths. As the "liver cancer capital" of the world, China (accounts for annually new cases globally45%），80%The above-mentioned patients were already in the middle or late stage at the time of diagnosis, and the effect of traditional treatment methods (surgery, intervention, targeted drugs) was limited.5The survival rate is less than15%。

BAY 3547926The highlight lies in 'precise targeting'.+'Powerful Killing': The drug may identify liver cancer cells through specific molecular markers, carrying radioactive isotopes directly to the lesion and releasing high-energy rays locally. It is equivalent to installing a 'miniature nuclear bomb' on cancer cells, which can improve efficacy while reducing systemic toxicity. If clinical research proceeds smoothly, it has the potential to fill the treatment gap for patients with mid- to late-stage liver cancer.GPC3A New Treatment Option for Patients with Advanced Hepatocellular Carcinoma who are Positive, andRewrite the existing treatment landscape.